Horizon Space Acquisition II Business Summary

Horizon Space Acquisition II Corp. (HSPT) operates as a special purpose acquisition company (SPAC), a blank-check entity designed to facilitate a merger, asset acquisition, or similar business combination. As of February 2026, the company generates no operating revenue, with its primary value proposition centered on its definitive business combination agreement with SL BIO Ltd., a clinical-stage biomedical firm specializing in innovative cellular and gene therapies for oncology and regenerative medicine. Post-merger, the entity—to be renamed SL Science Holding Limited—intends to generate revenue through the commercialization of its biotechnology pipeline, strategic licensing agreements, and clinical partnerships. Within the competitive landscape, HSPT contends with other specialized acquisition vehicles such as Cantor Equity Partners, Launch One Acquisition Corp, and SilverBox Corp IV, positioning itself as a niche bridge for high-growth Asia-linked life sciences firms seeking access to U.S. capital markets. The company is currently led by Chairman and CEO Mingyu (Michael) Li, a seasoned Chinese private equity investor with an extensive background in cross-border transactions and executive leadership across multiple industries, supported by CFO Min Zhai. Upon the anticipated closing of the SL BIO merger in March 2026, leadership will transition to a team featuring William Wang as CEO and Chairman, Johnson Lau as CFO, and Dr. Ethan Shen as CTO, bringing deep expertise in translational medicine, immunotherapy, and biomanufacturing. The board is further strengthened by independent director nominees Joseph Levinson and Qian (Hebe) Xu, who provide specialized experience in corporate governance and investment banking. Notable institutional backing remains high, with approximately 70% of shares held by institutional investors, reflecting significant market confidence in the management’s ability to execute the transition into the healthcare sector.